

Oncology

Elsevier Editorial System(tm) for Clinical

Manuscript Draft

Manuscript Number:

Title: It's PRIMETIME: Post-operative avoidance of radiotherapy:
biomarker selection of women at very low risk of local recurrence

Article Type: Editorial

Keywords: Radiotherapy; breast cancer; cohort study; overtreatment;
biomarker

Corresponding Author: Ms. Cliona C Kirwan, BSc(Hons), MBBS, FRCS(gen),
PhD

Corresponding Author's Institution: University of Manchester

First Author: Cliona C Kirwan, BSc(Hons), MBBS, FRCS(gen), PhD

Order of Authors: Cliona C Kirwan, BSc(Hons), MBBS, FRCS(gen), PhD;
Charlotte E Coles, MRCP, FRCR, PhD

Manuscript Region of Origin: UNITED KINGDOM

University Hospital of South Manchester
Southmoor Road
Manchester
M23 9LT

Academic Division of Surgery
2nd Floor, Education and Research Centre
Tel: 0161 291 5859
Fax: 0161 291 5860
Email: cliona.kirwan@manchester.ac.uk

Miss Cliona Kirwan
NIHR Clinician Scientist in Surgical Oncology

16th February, 2016

Dear Duncan Gilbert,

Re: It's PRIMETIME: Post-operative avoidance of radiotherapy: biomarker selection of women at very low risk of local recurrence.

C. C. Kirwan, C.E. Coles

On behalf of the PRIMETIME Protocol Working Group

Thank you for considering the above editorial for publication in Clinical Oncology.

This editorial aims to introduce 'PRIMETIME', a prospective, biomarker-directed, Cancer Research UK-funded cohort study that will shortly be opening across the UK. PRIMETIME aims to identify a subgroup of women who can avoid radiotherapy following breast conserving surgery for breast cancer. Through immunohistochemical and clinical assessment, this study aims to identify women at such low risk of recurrent breast cancer, that the risks of radiotherapy are outweighed by the benefits. PRIMETIME will utilise the highly successful collaborations established by the START trial testing hypofractionation, and consolidated by the IMPORT and FASTForward trials. We anticipate the study opening to recruitment within 4-6 months, with the aim of recruiting 2,400 women across the UK.

This study represents an exciting collaboration between clinical oncologists, pathologists and surgeons, and aims to tackle the increasingly important issue of over-treatment.

Kind regards,

Yours sincerely,



Miss Cliona Kirwan PhD FRCS, on behalf of the authors and the PRIMETIME Trialists

Title:

It's PRIMETIME. Post-operative avoidance of radiotherapy: biomarker selection of women at very low risk of local recurrence

Author list: Cliona Clare Kirwan^a, Charlotte E. Coles^b

On behalf of the PRIMETIME Protocol Working Group

^a University of Manchester Department of Academic Surgery, South Manchester University Hospitals Trust, Southmoor Road, Manchester, M23 9LT, UK.

^bOncology Centre, Box 193, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ

Author degrees and affiliations:

C. C. Kirwan, MBBS BSc FRCS(gen) PhD

Email: cliona.kirwan@manchester.ac.uk

C.E. Coles, MRCP, FRCR, PhD

Email: charlotte.coles@addenbrookes.nhs.uk

Address for correspondence:

Miss Cliona Kirwan, BSc, MBBS, PhD, FRCS

Consultant Oncoplastic Breast Surgeon and NIHR Clinician Scientist in Surgical Oncology

Department of Academic Surgery

University Hospital of South Manchester

Manchester, M23 9LT

Tel: +44 (0)161-291-4436 / 5851

Fax: +44 (0)161-291-5863

Email: cliona.kirwan@manchester.ac.uk

Disclosures of commercial interest:

None.

Financial support:

PRIMETIME is funded by Cancer Research UK (Grant number: C17918/A20015).

Acknowledgements:

PRIMETIME is funded by Cancer Research UK (Grant number: C17918/A20015). Dr Coles is supported by the Cambridge National Institute of Health Research Biomedical Research Centre.

Ms Kirwan is supported by a NIHR Clinician Scientist Award.

Keywords:

Radiotherapy; breast cancer; cohort study; overtreatment; biomarker

Title:

It's PRIMETIME. Post-operative avoidance of radiotherapy: biomarker selection of women at very low risk of local recurrence

Author list: Cliona Clare Kirwan^a, Charlotte E. Coles^b

On behalf of the PRIMETIME Protocol Working Group

^a University of Manchester Department of Academic Surgery, South Manchester University Hospitals Trust, Southmoor Road, Manchester, M23 9LT, UK.

^bOncology Centre, Box 193, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ

Author degrees and affiliations:

C. C. Kirwan, MBBS BSc FRCS(gen) PhD

Email: cliona.kirwan@manchester.ac.uk

C.E. Coles, MRCP, FRCR, PhD

Email: charlotte.coles@addenbrookes.nhs.uk

Address for correspondence:

Miss Cliona Kirwan, BSc, MBBS, PhD, FRCS

Consultant Oncoplastic Breast Surgeon and NIHR Clinician Scientist in Surgical Oncology

Department of Academic Surgery

University Hospital of South Manchester

Manchester, M23 9LT

Tel: +44 (0)161-291-4436 / 5851 Fax: +44 (0)161-291-5863

Email: cliona.kirwan@manchester.ac.uk

Disclosures of commercial interest:

None.

Financial support:

PRIMETIME is funded by Cancer Research UK (Grant number: C17918/A20015).

Acknowledgements:

PRIMETIME is funded by Cancer Research UK (Grant number: C17918/A20015). Dr Coles is supported by the Cambridge National Institute of Health Research Biomedical Research Centre.

Ms Kirwan is supported by a NIHR Clinician Scientist Award.

Keywords:

Radiotherapy; breast cancer; cohort study; overtreatment; biomarker

Editorial:

After 40 years of improving, increasing and extending adjuvant breast cancer therapies, there are increasing concerns about overtreatment, with TIME magazine featuring this controversy on their October 2015 front cover. This editorial discusses the rationale and design of a new study, PRIMETIME, that investigates the safe avoidance of radiotherapy (RT) following breast conserving surgery (BCS) in patients at very low risk of recurrence.

Side effects from breast radiotherapy may now outweigh potential benefit in some patients

Radiotherapy is part of the current standard of care package and in the UK is recommended by the National Institute for Health and Care Excellence for all women with early invasive breast cancer after BCS. Radiotherapy to the conserved breast halves the rate of cancer relapse (local, regional or distant) and reduces breast cancer mortality by about one sixth [1]. These proportional benefits vary little between different subgroups, but the absolute benefits (number of women per 100 for whom relapse is prevented) vary substantially according to patient and tumour characteristics and can be very low. For example, the UK PRIME II trial (2003-2009) reported a 5-year local relapse rate of 1.3% (95% CI 0.2-2.3) in low risk early breast cancer patients (tumour \leq 3cm, oestrogen receptor [ER] positive, node negative) following BCS and RT compared to 4.1% (95% CI 2.4-5.7) after no RT ($p=0.002$)[2]. There was no excess of distant relapse, second cancers or deaths, suggesting that local relapses after BCS can be salvaged with further surgery (\pm RT) without increasing the risk of breast cancer death. In an unplanned subgroup analysis, ER-rich patients receiving RT had only a 2.4% absolute gain in local relapse over non-irradiated patients.

Side effects following breast RT still occur with modern techniques, and the rates and severity are the same irrespective of the magnitude of radiotherapy benefit. The 10-year analysis of the UK START trials testing RT fractionation in women with early breast cancer reported moderate/severe chronic adverse effects (breast shrinkage, pain, tenderness or hardness) in up to one-third of patients[3]. These side-effects impair quality of life and can cause psychological distress. Even using intensity-modulated radiotherapy, 12% of patients may have poor cosmesis at 5 years[4]. Breast cancer RT increases rates of major coronary events by 7.4%/Gy mean heart dose, with absolute risk of radiation induced cardiac toxicity increasing substantially in patients with pre-existing cardiac risk factors[5].

These risks support the assertion that if patients with a very low risk of local relapse can be reliably identified, then they may benefit from avoiding breast RT after complete microscopic excision of primary tumour. Identification of these individuals relies increasingly on the use of tumour biomarkers in the primary tumour.

Risk stratified medicine using biomarkers

Cancer treatment has entered an era of tailored medicine, which may be personalised to the individual or may stratify patient groups of similar risk. Basic clinico-pathological parameters (e.g. tumour size, grade, receptor status and nodal involvement) are being enhanced and even superseded by tumour genotyping. For example a 21-gene expression assay in breast cancer allows identification of patients with very low recurrence rates in the absence of adjuvant chemotherapy,

1 who would previously have received chemotherapy based on routine clinico-pathological
2 parameters only[6].

3
4 Genotyping techniques are expensive. In contrast, immunohistochemical (IHC) biomarkers are a
5 relatively inexpensive alternative that allows sub-typing of tumours into genetically distinct
6 categories based on IHC phenotype. IHC biomarkers have been shown to provide prognostic
7 information on local relapse following radiotherapy[7]. IHC4+clinical (IHC4+C) is a refinement of IHC
8 phenotyping that combines protein expression of ER, progesterone receptor (PgR), HER2 and Ki67
9 with clinico-pathological parameters to identify breast cancer patients at low, intermediate or high
10 risk of distant disease recurrence [8]. The TransATAC translational study on ATAC trial (Arimidex,
11 Tamoxifen Alone or Combined) demonstrated that IHC4+C provided comparable or more accurate
12 prognostic information than commercially available genotyping assays (Risk of Recurrence Score and
13 OncotypeDX respectively) for postmenopausal women treated with endocrine therapy [9]. The
14 IHC4+C score will be used within the PRIMETIME study, to identify patients at very low risk of
15 recurrence.
16
17
18
19

20 **Study Design**

21
22
23 PRIMETIME is a prospective, biomarker-directed cohort study. It intends to utilise the highly
24 successful collaborations established by the NCRI Standardisation of Radiotherapy (START) trial
25 testing hypofractionation, and consolidated by the IMPORT and FASTForward trials. The study
26 rationale is to obtain high quality, practice changing, clinical evidence supporting the safe avoidance
27 of radiotherapy for a highly selected subgroup of breast cancer patients, who are deemed to be at
28 such low risk of local relapse that the potential benefits associated with radiotherapy do not
29 outweigh the known risks.
30
31

32
33 This study aims to recruit women aged ≥ 60 years who have undergone breast conserving surgery for
34 invasive disease, with complete resection of tumour tissue. The final pathology will determine study
35 eligibility, with IHC4+C defining whether patients are 'very low' risk (<5% probability of distant
36 relapse at 10 years) and eligible for radiotherapy avoidance or not 'very low' risk, and therefore
37 require radiotherapy according to standard care (Figure 1). All patients must be recommended a
38 minimum of 5 years adjuvant endocrine therapy as per local policy.
39
40
41

42 To ensure sufficient time for IHC4+C calculation, there will be two stages to patient recruitment, i)
43 preoperative following diagnostic biopsy and ii) postoperative following definitive surgery and MDT
44 confirmation of eligibility.
45
46

47 Stage 1: Patients preoperatively assessed as potentially eligible for study entry will be approached
48 before definitive breast conserving surgery (Figure 1). Following explanation of the PRIMETIME
49 study, consent will be sought for sample provision to a central laboratory for IHC4+C testing.
50
51

52 Stage 2: Following definitive breast conserving surgery and confirmation of eligibility, patients will be
53 offered the option of participating in the study. Patients with a 'very low' risk of relapse, based on
54 IHC4+C will be recommended avoidance of radiotherapy. Patients with a 'low', 'intermediate' or
55 'high' risk of relapse, will be recommended radiotherapy. For all patients, regardless of risk category,
56 all other anti-cancer treatments will be administered and managed according to local practice.
57
58
59
60
61
62
63
64
65

1 The primary endpoint is ipsilateral breast disease rate at 5 years. PRIMETIME requires recruitment of
2 2400 patients at the pre-operative stage, to allow 1550 patients to actively avoid of radiotherapy,
3 based on a local relapse rate, in the absence of radiotherapy, of $\leq 4\%$ at 5 years. The two stage study
4 design necessitates engagement of the surgical community to facilitate recruitment at the pre-
5 operative stage. The study has been designed through a collaboration between surgeons and clinical
6 oncologists, with surgeons being a fundamental part of the trial management group. This study has
7 the support of the Association of Breast Surgery. Given the previous success of surgical-clinical
8 oncology collaboration with IMPORT high (which necessitated cavity clip insertion at surgery, and
9 achieved a 93% compliance rate) we anticipate similar successful teamwork. PRIMETIME also has
10 strong support from patient advocates who have been involved in every stage of the study evolution
11 and will continue to play an active role.
12
13
14

15
16 Follow-up data will be collected prospectively during routine clinical follow up. Given that this group
17 of patients can relapse after 5 years following treatment, it is essential that outcomes are monitored
18 for at least 10 years. This includes yearly mammograms for 10 years for those patients not receiving
19 radiotherapy. As a further aim of this study, we shall determine the accuracy of outcomes reported
20 on Cancer Services and Outcomes Dataset (COSD), the National Radiotherapy Dataset (RTDS), the
21 Systemic Anti-Cancer Therapy Dataset (SACT) and the Hospital Episodes Statistics (HES) compared to
22 prospective research data collection. This will allow us to validate the use of routinely collected NHS
23 outcome data as a new cost-effective method of long term research data collection.
24
25
26

27 PRIMETIME is designed as a cohort study, rather than a randomised trial, after extensive discussions
28 with the funders (Cancer Research UK), the trialists, UK Breast Intergroup, National Cancer Research
29 Institute Breast Clinical Studies Group and patient advocates. This study design was chosen in part
30 because the impact of radiotherapy on local recurrence rates is already known, and thus does not
31 need determining by a randomised trial. PRIMETIME aims to define a subgroup of women at
32 sufficiently low risk of local recurrence, that the reduction in local recurrence rates provided by
33 radiotherapy is not clinically relevant. A simple cohort study will facilitate rapid accrual, as patient
34 acceptance of randomisation is recognised to negatively impact on recruitment. In addition,
35 PRIMETIME design is in line with a similar Canadian cohort study, LUMINA, allowing future meta-
36 analysis.
37
38
39
40
41

42 **Conclusion**

43
44 Primetime has a novel design utilising biomarker selection of patients at 'very low' risk of recurrence
45 for avoidance of breast radiotherapy within a prospective cohort study with at least 10 years follow
46 up. It is hoped that IHC4+C will prove an effective, yet inexpensive method for risk stratification that
47 can be adopted as part of standard care. In addition, it is anticipated that this study will pave the
48 way for use of routine NHS outcome data as a cost-effective method of long term follow up in future
49 trials. In an era of overdiagnosis and overtreatment being a regular source of negative media
50 attention, this study could not be more timely.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

PRIMETIME




Figure 1: Schema for PRIMETIME Study. ER+, Oestrogen Receptor Positive; IHC4+C, Immunohistochemistry4 + Clinical Score; WLE, wide local excision; SLNB, sentinel lymph node biopsy; ET, endocrine therapy; RT, radiotherapy. Eligibility criteria, to allow risk group determination, includes final pathology confirmation of AJCC staging of pT1/pN0/M0; grade 1 or 2 invasive breast cancer; oestrogen (ER) and progesterone receptor (PR) positive and human epidermal growth factor receptor (HER2) negative according to local practice; and a IHC4+C recurrence probability score.

References

- 1
2 [1] Darby, S., et al., *Effect of radiotherapy after breast-conserving surgery on 10-year recurrence*
3 *and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women*
4 *in 17 randomised trials*. Lancet, 2011. **378**(9804): p. 1707-16.
- 5
6 [2] Kunkler, I.H., et al., *Breast-conserving surgery with or without irradiation in women aged 65*
7 *years or older with early breast cancer (PRIME II): a randomised controlled trial*. Lancet
8 *Oncol*, 2015. **16**(3): p. 266-73.
- 9
10 [3] Haviland, J.S., et al., *The UK Standardisation of Breast Radiotherapy (START) trials of*
11 *radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up*
12 *results of two randomised controlled trials*. Lancet Oncol, 2013. **14**(11): p. 1086-94.
- 13
14 [4] Mukesh, M.B., et al., *Randomized controlled trial of intensity-modulated radiotherapy for*
15 *early breast cancer: 5-year results confirm superior overall cosmesis*. J Clin Oncol, 2013.
16 **31**(36): p. 4488-95.
- 17
18 [5] Darby, S.C., et al., *Risk of ischemic heart disease in women after radiotherapy for breast*
19 *cancer*. N Engl J Med, 2013. **368**(11): p. 987-98.
- 20
21 [6] Sparano, J.A., et al., *Prospective Validation of a 21-Gene Expression Assay in Breast Cancer*. N
22 *Engl J Med*, 2015. **373**(21): p. 2005-14.
- 23
24 [7] Bane, A.L., et al., *Tumor factors predictive of response to hypofractionated radiotherapy in a*
25 *randomized trial following breast conserving therapy*. Ann Oncol, 2014. **25**(5): p. 992-8.
- 26
27 [8] Cuzick, J., et al., *Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-*
28 *67, and human epidermal growth factor receptor 2 immunohistochemical score and*
29 *comparison with the Genomic Health recurrence score in early breast cancer*. J Clin Oncol,
30 2011. **29**(32): p. 4273-8.
- 31
32 [9] Dowsett, M., et al., *Comparison of PAM50 risk of recurrence score with oncotype DX and*
33 *IHC4 for predicting risk of distant recurrence after endocrine therapy*. J Clin Oncol, 2013.
34 **31**(22): p. 2783-90.
- 35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1 Study Schema

